Retatrutide
Retatrutide is the first compound to hit three metabolic receptors at once — GLP-1, GIP, and glucagon. In Phase 3 trials it produced the largest weight reduction ever reported for a drug in this class, alongside improvements in blood sugar, blood pressure, cholesterol, and joint pain. It is also the most powerful compound most people will ever consider, and it is not approved anywhere in the world.
Overview
Retatrutide is a 39-amino-acid peptide developed by Eli Lilly. Where semaglutide activates one receptor and tirzepatide activates two, retatrutide activates three: GLP-1, GIP, and glucagon. That third receptor is what makes it different — and it's the reason the weight loss numbers are larger than anything before it.
It is investigational. As of mid-2026 it has completed several Phase 3 trials with strong results, but it is not approved by the FDA, the EMA, or any other regulator, and there is no prescription pathway for it anywhere.
Key benefits
| Benefit | Description |
|---|---|
| Weight reduction | The largest effect reported for any drug in this class — up to roughly 28–30% of body weight in Phase 3 trials at the highest dose. |
| Blood sugar | Lowers HbA1c and fasting glucose; improves insulin sensitivity. Studied specifically in type 2 diabetes. |
| Cardiometabolic markers | Reduced triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference, and inflammatory markers. |
| Joint pain | In people with obesity and knee osteoarthritis, substantial reductions in pain scores and improved physical function. |
| Appetite regulation | Pronounced reduction in food intake and food-related preoccupation through combined GLP-1 and GIP signaling. |
| Energy expenditure | The glucagon arm increases metabolic rate and drives fat mobilization — the mechanism the other drugs in this class don't have. |
Mechanisms of action
Three receptors, three jobs, one molecule.
Slows stomach emptying, increases satiety through the hypothalamus, and boosts glucose-dependent insulin release. This is the appetite arm.
Works alongside insulin to help cells take up blood sugar and use it for energy. Also appears to reduce nausea signalling, which is part of why dual agonists tolerate better than expected.
Raises energy expenditure and mobilizes stored fat, particularly in the liver. This is the arm that's unique to retatrutide.
The first two reduce how much energy comes in. The third increases how much goes out. Attacking both sides at once is why the effect size exceeds compounds that only do the first part.
Your body is like a busy little town.
Day and night it has important jobs to do. There's an energy factory turning your food into fuel, a fuel station keeping your levels just right, and a hunger center that tells you when it's time to eat.
To get all those jobs done, your body sends out tiny messengers, like little mail carriers zipping around with notes. The notes say things like "Time to eat!" or "You're full!" or "Use this fuel!" Grown-ups call these messengers hormones.
But sometimes the messages get mixed up
The "You're full!" note might show up too late — so your tummy keeps asking for more, even when it already has plenty.
Or your body holds onto extra fuel and tucks it away, instead of using it up.
Along comes retatrutide
Here's the really cool part. It's like one super-letter that can knock on three mailboxes at once.
Those three mailboxes belong to three helpers your body already knows. Retatrutide wakes them up and says, "Let's get to work!"
She taps your brain on the shoulder and says, "You're full now — you can stop. Nice work!"
She also tells your tummy to empty s·l·o·w·l·y, like a bathtub draining one drip at a time. Your food stays cozy in there longer, so you stay full longer and don't get hungry again so fast.
When you eat, your food turns into a kind of sugar-fuel that floats in your blood. Her job is making sure it doesn't just pile up there.
So she calls in a special tool: insulin, which works just like a key. It unlocks tiny doors on your cells so the sugar-fuel can hop inside and give them energy. The Sugar Sorter makes sure the right number of keys show up at exactly the right time.
This one is extra special, because not every medicine has it. His job is to turn up your body's engine, so you burn more fuel — even when you're sitting still.
Think of your body like a campfire. The Engine Spark is a little puff of air that makes the fire burn brighter and warmer, using up extra fuel your body had tucked away for later. More burning means more energy used up. Whoosh!
A team of three
Now your body has a whole team working together: "You're full!" "Fuel, this way!" "Burn it bright!"
Retatrutide is usually a tiny shot, just once a week. It doesn't work all at once, like flipping a light switch. It works slowly and gently, turning a dial little by little over many weeks. Slow and steady wins the race.
A helper, not magic
Retatrutide is a helper, not a magic wand. It works best alongside the everyday good stuff — good food, moving your body, plenty of sleep.
And there's one more thing worth knowing. When the Engine Spark is burning through the town's stored fuel this fast, the town still has workers who need feeding. The Fullness Friend is very good at her job now — good enough that the town can end up short on what it genuinely needs.
So the three helpers do their part. And you do yours. That's teamwork.
Considerations
Retatrutide is not approved anywhere in the world. It has strong Phase 3 data and Lilly is pursuing approval, but as of now there is no regulator-reviewed label, no approved dose, and no prescription pathway. Every non-trial use is happening outside that system.
The trials were run with clinical supervision, structured dose escalation, dietary guidance, and monitoring. Those things aren't incidental to the results — dropping them changes both the safety picture and the outcome.
Losing a quarter of your body weight means losing lean mass too unless protein intake and resistance training are deliberate. This is the most common way people get a bad outcome from a good result.
Side effect rates climb sharply with dose. Trials stepped up every four weeks. Rushing is the single biggest driver of a miserable experience.
In the CV outcomes trial, major cardiac events were numerically similar between drug and placebo, with a wide confidence interval. Risk factors improved; events did not.
A consistent class effect, and the glucagon arm adds to it. Worth knowing your baseline.
Fast weight reduction from any cause raises gallbladder risk. This produces some of the fastest loss ever recorded.
Appetite returns. Regain after discontinuation is well documented across this whole drug class. There's no exit plan built into the vial.
What it needs to work
This is the compound where foundations matter most, and it's the one people most often skip them on. Retatrutide makes you eat less — that's the point. But eating less doesn't reduce what your body still requires. It just makes it harder to get.
The single most important one. Appetite suppression this strong plus rapid weight loss will cost you muscle unless protein intake is deliberate and prioritized in every meal you do eat.
Eating far less means taking in far less sodium, potassium, and magnesium — and GI losses compound it. Fatigue, headaches, dizziness and cramps in the first weeks are frequently this, not the drug itself.
Thirst cues drop along with hunger cues. Dehydration is common and makes every other side effect feel worse.
The glucagon arm increases energy expenditure while intake falls. Running very low carbohydrate on top of that is a reliable route to feeling flat and losing training quality.
Slowed gastric emptying plus reduced food volume makes constipation one of the most common complaints. Easier to prevent than to fix.
Not a nutrient, but it belongs here. It's the strongest lever you have for keeping the weight you lose from being muscle.
The research, in detail
Retatrutide has more human trial data behind it than anything else in this library. The TRIUMPH program spans eight Phase 3 trials plus a cardiovascular outcomes study.
- Phase 3 — obesity, 2,339 participantsTRIUMPH-1At 80 weeks: 17.6% weight loss at 4 mg, 23.7% at 9 mg, 25.0% at 12 mg, versus 3.9% on placebo. At 12 mg, 62.5% of participants lost at least 25% of body weight and 27.2% lost at least 35%. A subgroup continued to 104 weeks and reached roughly 30%.
- Phase 3 — obesity + knee osteoarthritisTRIUMPH-428.7% average weight loss (71.2 lb) at 68 weeks on 12 mg. Pain scores fell 75.8%, and more than one in eight participants finished the trial free of knee pain.
- Phase 3 — type 2 diabetesTRIUMPH-2 / TRANSCEND-T2D-1Met primary endpoints for weight and A1C. Weight loss in diabetes is consistently smaller than in non-diabetic populations — 16.8% at 40 weeks in the earlier readout.
- Phase 3 — established cardiovascular diseaseTRIUMPH-3Triglycerides down 37.0%, non-HDL cholesterol down 16.5%, systolic blood pressure down 9.3 mmHg, waist circumference down 19 cm, hsCRP down 51.2%. Major cardiac events: 27 on retatrutide versus 23 on placebo, hazard ratio 1.12 with a wide confidence interval — no benefit demonstrated on events themselves.
- OngoingRemaining TRIUMPH trialsObstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and fatty liver disease. Several readouts expected through 2026.
What it feels like
Unlike most compounds in this library, you will notice this one. Food stops being interesting. The mental chatter about eating quiets down — people describe it as the loudest and strangest part. Meals end early and stay ended.
The first two weeks after each dose increase are usually the hardest. Nausea, unpredictable digestion, and a general flatness are common while the body adjusts, and they typically settle before the next step up.
Dosing
| Phase | Trial protocol |
|---|---|
| Starting dose | 2 mg weekly |
| Escalation | Every 4 weeks |
| Maintenance doses studied | 4, 9, or 12 mg weekly |
| Time to full dose | Several months |
| Trial duration | 68–104 weeks |
| Half-life | ~6 days |
Mixing & storage
Storage
Stable long-term until reconstituted.
Refrigerate at 2–8°C. With weekly dosing a vial lasts a while, so date the label.
Swirl to dissolve. Agitation damages peptides.
Clear solution only. Cloudiness or particulates mean don't use it.
Side effects
Gastrointestinal effects dominate, and they scale with dose. From the Phase 3 diabetes trial, rates at 4 mg / 9 mg / 12 mg versus placebo:
| Effect | 4 / 9 / 12 mg vs placebo |
|---|---|
| Diarrhea | 27% / 34% / 34% vs 13% |
| Nausea | 14% / 21% / 28% vs 8% |
| Constipation | 14% / 16% / 17% vs 9% |
| Vomiting | 6% / 10% / 16% vs low |
| Decreased appetite | 6% / 12% / 17% vs 5% |
Most of these are worst in the weeks following a dose increase and settle as the body adjusts. Slower escalation is the main lever. Also reported across trials: increased heart rate, and skin sensitivity at higher doses.
Severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis). Persistent vomiting with an inability to keep fluids down. Signs of gallbladder trouble — pain under the right ribs, fever, yellowing of the skin or eyes.
Sourcing
Retatrutide has no approved pharmaceutical version, which means everything available is a research compound. Given how potent it is, what's in the vial matters more here than almost anywhere.
Lot number should match your vial. A generic PDF reused across the catalog isn't a COA.
The actual chart, not a "99%" claim on a graphic.
Purity tells you how much of one thing is in there. Mass spec tells you it's the right thing. Both matter.
Reported in EU/mg, typically under 0.1. Frequently omitted.
Common questions
Is retatrutide approved?
No — not in the US, EU, or anywhere else. Phase 3 trials have completed successfully and Lilly is pursuing approval, but there is currently no approved label and no prescription pathway.
How is it different from semaglutide and tirzepatide?
Semaglutide hits one receptor, tirzepatide hits two, retatrutide hits three. The third — glucagon — raises energy expenditure rather than just lowering intake. That's why the weight loss is larger, and part of why the GI side effects are too.
How often do I take it?
Once weekly in every trial. The half-life is around six days. Charts listing it several times per week don't match how it was studied.
Will I lose muscle?
Some, unless you work at not doing so. Losing 25–30% of body weight always includes lean mass. Prioritizing protein and resistance training are the two things that meaningfully change that ratio.
What happens if I stop?
Appetite returns and regain is common — well documented across this entire drug class. Worth thinking about before starting, not after.
Why do I feel so drained?
Often electrolytes, hydration, or simply not eating enough protein rather than the compound itself. Increasing the dose in response to feeling flat usually makes it worse.
